Visão geral da empresa
A clinical-stage biopharmaceutical entity, ORIC Pharmaceuticals, Inc. focuses its operational efforts on the discovery and development of novel therapies designed to counteract resistance mechanisms inherent in various cancer types within the United States market. The company operates within the broader Healthcare sector, specifically classified under the Biotechnology industry, which implies a business model heavily reliant on research and development cycles and the eventual approval of proprietary drugs before generating significant commercial revenue. As of the latest data, ORIC holds a market capitalization of $1.01 billion and employs a workforce of 104 individuals to execute its strategic initiatives. The combination of a substantial market cap exceeding one billion dollars and the absence of reported revenue highlights the company's position as a pre-commercial asset where value is derived primarily from intellectual property and potential future product approvals rather than current sales performance. This valuation structure is typical for biotechnology firms in the clinical stage, where the market prices in future cash flow potential from upcoming clinical trials rather than historical financial performance.
Saúde financeira
The financial statements for the trailing twelve months indicate a revenue figure of N/A, reflecting the lack of commercial product sales at this stage, while the net income stands at a loss of $-129,468,000 and the EBITDA is reported at $-141,784,000. The absence of revenue combined with significant net losses reveals a cost structure dominated by high research and development expenditures and operational burn rates typical of clinical-stage development. Free cash flow is reported at $-69,096,496, which indicates that the company is consuming cash to fund its operations and clinical trials rather than generating positive cash flow from sales. The company maintains a cash balance of $281.49 million, which provides a buffer against its current burn rate and debt obligations, suggesting a degree of financial runway despite the negative operating cash flow. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that signifies the company has not yet achieved commercial scale or cost recovery associated with selling products. The balance sheet shows total debt of $7.44 million against cash of $281.49 million, resulting in a debt-to-equity ratio of 1.94, which suggests a leveraged position relative to equity but is mitigated by the large cash reserve. The current ratio is an exceptionally high 14.13, indicating that the company possesses a very strong ability to meet its short-term liabilities with its current assets, primarily driven by its substantial cash holdings. Return on Equity is calculated at -41.3% and Return on Assets at -26.2%, metrics that reveal management is currently utilizing capital to generate losses rather than profits, a normal phenomenon for early-stage development but one that reflects a negative return on invested capital in the present period.
Avaliação de valorização
Valuation multiples for ORIC present a complex picture due to the lack of profitability, with the P/E Ratio (TTM) listed as N/A and a Forward P/E of -5.84. The negative forward P/E ratio implies that the market is pricing the stock based on anticipated future earnings that are currently projected to be negative, rather than on trailing earnings power. The Price to Book ratio is 2.32, which indicates that the market values the company at a premium of 132% over its net asset book value, reflecting the intangible value of its pipeline and clinical data. Alternative valuation metrics such as Price to Sales and EV/EBITDA are both N/A or negative (-4.47 for EV/EBITDA), suggesting that traditional valuation models based on revenue or earnings multiples are not applicable for a pre-revenue entity with negative EBITDA. The stock has demonstrated significant price volatility over the past year, trading between a 52-week low of $3.90 and a 52-week high of $14.93. At the time of the latest data, the current price sits at a level that must be interpreted relative to this wide range, where the 52-week high of $14.93 represents a peak valuation that the stock has reached during its trading history. The Beta is 1.36, meaning the stock is expected to be 36% more volatile than the broader market, which is consistent with the high-risk profile of small-cap biotechnology stocks.
Growth & Income
Growth metrics for the company are characterized by the absence of historical commercial data, with Revenue Growth (YoY) and Earnings Growth (YoY) both listed as N/A. Since there is no revenue baseline, earnings cannot be growing faster or slower than revenue in a traditional sense, as the company has not yet crossed the threshold of commercial product sales. As a non-dividend payer, the company reports a Dividend Yield of N/A and a Payout Ratio of 0.0%, which confirms that it does not distribute any portion of its earnings to shareholders. Instead of paying dividends, the company operates on a model where it retains and reinvests its capital, primarily the $281.49M in cash, into the advancement of its clinical stage product candidates like enozertinib. The overall growth and income profile is defined by a focus on capital appreciation through potential future commercialization rather than current income generation or dividend yields.